| scholarly article | Q13442814 |
| P356 | DOI | 10.1097/COC.0B013E31804B40BB |
| P698 | PubMed publication ID | 17762434 |
| P50 | author | Fa Chyi Lee | Q124061141 |
| Yehuda Patt | Q8051301 | ||
| P2093 | author name string | S Gail Eckhardt | |
| Milind Javle | |||
| Edward Lin | |||
| Glen R Justice | |||
| Alice Bexon | |||
| Joseph R Salvatore | |||
| James E Liebmann | |||
| Dimitrios Diamandidis | |||
| Wayne Keiser | |||
| P433 | issue | 4 | |
| P921 | main subject | metastatic colon cancer | Q108566365 |
| colorectal carcinoma | Q25493920 | ||
| phase II clinical trial | Q42824440 | ||
| colorectal cancer | Q188874 | ||
| irinotecan | Q412197 | ||
| capecitabine | Q420207 | ||
| P304 | page(s) | 350-357 | |
| P577 | publication date | 2007-08-01 | |
| P1433 | published in | American Journal of Clinical Oncology | Q2886177 |
| P1476 | title | Capecitabine plus 3-weekly irinotecan (XELIRI regimen) as first-line chemotherapy for metastatic colorectal cancer: phase II trial results | |
| P478 | volume | 30 |
| Q46271972 | A phase I study of combination therapy with S-1 and irinotecan (CPT-11) in patients with advanced colorectal cancer |
| Q99551782 | Association between MDR1 polymorphisms and XELIRI and XELOX chemoresistance in Saudi patients with colorectal cancer |
| Q35913223 | Bevacizumab-based therapies in the first-line treatment of metastatic colorectal cancer |
| Q36611697 | Bevacizumab-containing regimens after cetuximab failure in Kras wild-type metastatic colorectal carcinoma. |
| Q37400585 | Capecitabine in combination with irinotecan (XELIRI), administered as a 2-weekly schedule, as first-line chemotherapy for patients with metastatic colorectal cancer: a phase II study of the Spanish GOTI group |
| Q21260391 | Capecitabine plus Irinotecan (XELIRI regimen) compared to 5-FU/LV plus Irinotecan (FOLFIRI regimen) as neoadjuvant treatment for patients with unresectable liver-only metastases of metastatic colorectal cancer: a randomised prospective phase II trial |
| Q33519035 | Generalizability of toxicity data from oncology clinical trials to clinical practice: toxicity of irinotecan-based regimens in patients with metastatic colorectal cancer |
| Q38081864 | Management of advanced colorectal cancer, Part 1. |
| Q92389550 | Multicenter phase II study of biweekly CAPIRI plus bevacizumab as second-line therapy in patients with metastatic colorectal cancer (JSWOG-C3 study) |
| Q38167675 | Palliative treatment of metastatic colorectal cancer: what is the optimal approach? |
| Q36968457 | Phase 1 Study of ABT-751 in Combination With CAPIRI (Capecitabine and Irinotecan) and Bevacizumab in Patients With Advanced Colorectal Cancer |
| Q37481906 | Phase I/II study of sequential therapy with irinotecan and S-1 for metastatic colorectal cancer |
| Q34991668 | Phase II study of weekly irinotecan and capecitabine treatment in metastatic colorectal cancer patients |
| Q27021105 | Review of systemic therapies for locally advanced and metastatic rectal cancer |
| Q37612945 | Treatment of metastatic colorectal cancer in the elderly |
| Q37815612 | Update on capecitabine alone and in combination regimens in colorectal cancer patients |
Search more.